| Sydney, Australia – 26 October 2018 – Recce Pharma Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it will be represented at the World Anti-Microbial Resistance Congress in Washington D.C., 25 - 26 October 2018. The conference features 150 speakers from 20 countries and is a leading international forum for researchers, investors, businesses and governments working to address antibiotic resistance. Recce Executive Chairman Dr Graham Melrose said, “There is growing international interest in our new class of broad-spectrum synthetic antibiotic technology. With a range of meetings secured, this event allows us to efficiently engage with potential business and clinical partners to discuss commercial and clinical opportunities as we advance towards the start of human clinical trials”. Recce’s lead compound, RECCE® 327, is being developed as a new class of antibiotic, for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. It was awarded Qualified Infectious Disease Product (QIDP) designation in late-2017, as part of the US Generating Antibiotic Incentives Now (GAIN) Act, labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. In 2018, the Company successfully secured almost half of its R&D budget from Australian Government funding. | 
